Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.

American Journal of Physiology. Renal Physiology
Karen M HallowDavid W Boulton

Abstract

The mechanisms of cardiovascular and renal protection observed in clinical trials of sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) are incompletely understood and likely multifactorial, including natriuretic, diuretic, and antihypertensive effects, glomerular pressure reduction, and lowering of plasma and interstitial fluid volume. To quantitatively evaluate the contribution of proposed SGLT2i mechanisms of action on changes in renal hemodynamics and volume status, we coupled a mathematical model of renal function and volume homeostasis with clinical data in healthy subjects administered 10 mg of dapagliflozin once daily. The minimum set of mechanisms necessary to reproduce observed clinical responses (urinary sodium and water excretion, serum creatinine and sodium) was determined, and important unobserved physiological variables (glomerular pressure, blood and interstitial fluid volume) were then simulated. We further simulated the response to SGLT2i in diabetic virtual patients with and without renal impairment. Multiple mechanisms were required to explain the observed response: 1) direct inhibition of sodium and glucose reabsorption through SGLT2, 2) SGLT2-driven inhibition of Na+/H+ exchanger 3 sodium reabsorpt...Continue Reading

References

Jul 15, 1990·Annals of Internal Medicine·R W Schrier
Jun 15, 2007·Journal of the American Society of Nephrology : JASN·Robert W Schrier
Jul 4, 2009·Seminars in Dialysis·Jens Titze
Jul 10, 2010·Journal of the American Society of Nephrology : JASN·Volker VallonTimo Rieg
Jan 14, 2011·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Volker Vallon
Feb 18, 2012·Annual Review of Physiology·Volker Vallon, Scott C Thomson
Feb 22, 2012·Nature Reviews. Nephrology·Imed HelalRobert W Schrier
Oct 5, 2012·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Michael W Brands, M Marlina Manhiani
May 15, 2013·Diabetes, Obesity & Metabolism·H J Lambers HeerspinkJ List
Jan 10, 2014·Current Opinion in Nephrology and Hypertension·Jens Titze
Nov 18, 2015·Current Opinion in Nephrology and Hypertension·Aleksandra Novikov, Volker Vallon
Jan 29, 2016·European Heart Journal·David FitchettUNKNOWN EMPA-REG OUTCOME® trial investigators
Feb 5, 2016·CPT: Pharmacometrics & Systems Pharmacology·W WangD A James
Jun 12, 2016·Journal of the American Society of Nephrology : JASN·Michael J CoadyJean-Yves Lapointe
Jun 12, 2016·Diabetes Care·Ele FerranniniEric Mayoux
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Feb 6, 2017·Journal of the American Society of Nephrology : JASN·Markus P SchneiderKai-Uwe Eckardt
Mar 24, 2017·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Debra L IrsikMichael W Brands
May 21, 2017·The American Journal of Medicine·Christoph Wanner
May 27, 2017·CPT: Pharmacometrics & Systems Pharmacology·K M Hallow, Y Gebremichael
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Oct 13, 2017·Diabetes, Obesity & Metabolism·Karen M HallowDavid W Boulton
Jan 25, 2018·American Journal of Physiology. Renal Physiology·Anita T Layton, Volker Vallon

❮ Previous
Next ❯

Citations

Dec 20, 2018·American Journal of Physiology. Renal Physiology·Anita T Layton, Jennifer C Sullivan
Apr 27, 2019·Expert Opinion on Therapeutic Patents·Jyotsana Pandey, Akhilesh K Tamrakar
Nov 14, 2019·American Journal of Physiology. Cell Physiology·Danúbia Silva Dos SantosAdriana C C Girardi
Sep 29, 2020·Circulation·Janani RangaswamiUNKNOWN American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Arteriosclerosis, Thrombosis and Vasc
Feb 1, 2020·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Daniël H van Raalte, Petter Bjornstad
Apr 14, 2021·Journal of the American Society of Nephrology : JASN·Flávio A Borges-JúniorAdriana C C Girardi
Nov 15, 2019·Morphologie : Bulletin De L'Association Des Anatomistes·S Randall Thomas
Jul 24, 2021·The Journal of Membrane Biology·Jiang LiuJoseph I Shapiro
Jul 31, 2021·World Journal of Diabetes·Jelena Marinkovic-RadosevicAnna Mrzljak

❮ Previous
Next ❯

Software Mentioned

R

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Risk Reduction

Prevention of cardiovascular disease is an important health initiative. Risk reduction including physical activity, smoking cessation, diet, blood pressure lowering drugs and pharmacotherapy. Here is the latest research on cardiovascular risk reduction.